Rapamycin (Sirolimus) and Rapamycin (Sirolimus) for Human longevity
Each entry’s own grades, side by side. A grade says how strong the evidence is for one outcome — it does not rank one entry over the other.
Compound or practice
Rapamycin (Sirolimus)
A prescription mTOR inhibitor that extends lifespan in animals like nothing else — and the most serious off-label longevity experiment in humans.
Grade B2 graded outcomesrevised Jul 10, 2026
A structured monograph in Prometheus's bundled library. Its grades are the monograph's own reading of the evidence, not a peer-reviewed review.
Evidence brief
Rapamycin (Sirolimus) for Human longevity
Evidence grade D — No outcome data yet
Grade D1 graded outcomerevised Jul 10, 2026
Assembled by the app from other entries in this library. It adds no evidence of its own — follow the links to the entries it draws on.
Graded in both
Outcomes are matched by name. Two entries can describe the same outcome in different words, so one listed further down may still be graded in the other.
| Outcome | Rapamycin (Sirolimus) | Rapamycin (Sirolimus) for Human longevity |
|---|---|---|
| Human longevity | Evidence grade DUnclear effectlowNo outcome data yet | Evidence grade DUnclear effectlowNo outcome data yet |
Graded only in Rapamycin (Sirolimus)
- Lifespan (animals) Large effectEvidence grade A
Graded only in Rapamycin (Sirolimus) for Human longevity
None — every outcome it grades is graded in both.
What each entry says about the other
- Rapamycin (Sirolimus) for Human longevity’s entry · Goes with: Read the full Rapamycin (Sirolimus) monograph
Both columns are read from the entries as they stand in this library. A comparison is not advice to take either one, and it is no substitute for a clinician who knows the person.